Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Scientific Initiatives Will Not Change After Election, Crawford Predicts

Executive Summary

FDA's scientific initiatives will not be affected by the outcome of the Nov. 2 Presidential elections, Acting Commissioner Lester Crawford said Oct. 10 at an R&D conference sponsored by Phacilitate in Geneva, Switzerland

You may also be interested in...



Pharmacogenomics working group (correction)

GlaxoSmithKline Director-Clinical Pharmacogenetics Mark Watson, MD/PhD, is the chair of the Pharmacogenetics Working Group. "The Pink Sheet" incorrectly reported that Wyeth Senior Director-Regulatory Affairs Ronald Salerno was the chair of the pharmacogenetics working group (1"The Pink Sheet" Oct. 11, 2004, p. 13). Salerno stepped down in July. The working group is not sponsored by the Pharmaceutical Research & Manufacturers of America; it was formed from the pharmacogenetics special interest group of the Drug Information Association in 2000. PhRMA's Genomics Division, which was formed in 2002, is chaired by Millennium Pharmaceuticals Director-Regulatory Strategy & Intelligence Christopher Webster, PhD...

Pharmacogenomics working group (correction)

GlaxoSmithKline Director-Clinical Pharmacogenetics Mark Watson, MD/PhD, is the chair of the Pharmacogenetics Working Group. "The Pink Sheet" incorrectly reported that Wyeth Senior Director-Regulatory Affairs Ronald Salerno was the chair of the pharmacogenetics working group (1"The Pink Sheet" Oct. 11, 2004, p. 13). Salerno stepped down in July. The working group is not sponsored by the Pharmaceutical Research & Manufacturers of America; it was formed from the pharmacogenetics special interest group of the Drug Information Association in 2000. PhRMA's Genomics Division, which was formed in 2002, is chaired by Millennium Pharmaceuticals Director-Regulatory Strategy & Intelligence Christopher Webster, PhD...

FDA Wants To Be “Model” Agency: Preparing For Clinical Trial Simulations

FDA plans to make greater use of mathematical and statistical models to guide drug development and approval decisions, Center for Drug Evaluation & Research Scientific Advisor Donald Stanski said Oct. 5 at a R&D conference sponsored by Phacilitate in Geneva, Switzerland

Related Content

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel